低剂量艾司氯胺酮对中高危阻塞性睡眠呼吸暂停患者胃镜检查中低氧血症的影响:前瞻性随机对照试验方案
本研究为单中心、双盲、随机对照优效性试验,拟纳入294例STOP-Bang评分≥3分、18-90岁接受胃镜检查的患者,1:1随机接受艾司氯胺酮(0.25 mg/kg)联合丙泊酚或生理盐水安慰剂联合丙泊酚,按年龄和OSA严重程度分层,主要结局为低氧血症(SpO2<90%持续>10秒)发生率。
要点
- 拟纳入294例STOP-Bang评分≥3分、18-90岁胃镜检查患者,1:1随机分组。
- 干预组为艾司氯胺酮0.25 mg/kg联合丙泊酚,对照组为生理盐水安慰剂联合丙泊酚。
- 主要结局为低氧血症(SpO2<90%持续>10秒)发生率。
核心结论
- 该试验方案旨在严格评估艾司氯胺酮改善OSA患者镇静安全性的潜力,填补围操作期护理的关键空白。
研究设计与样本
- 单中心、双盲、随机对照优效性试验,计划纳入294例STOP-Bang评分≥3分、18-90岁接受胃镜检查的患者。
- 参与者按1:1随机接受艾司氯胺酮(0.25 mg/kg)联合丙泊酚或生理盐水安慰剂联合丙泊酚,按年龄(18-65岁 vs. >65岁)和OSA严重程度(STOP-Bang 5-6分 vs. ≥7分)分层。
主要发现
- 主要结局为低氧血症(SpO2<90%持续>10秒)发生率。
- 次要结局包括严重低氧血症(SpO2≤75%或SpO2≤90%持续≥60秒)、低氧血症持续时间、紧急气道管理、丙泊酚用量、血流动力学稳定性、不自主体动、操作/恢复时间及临床医生满意度(采用10 cm视觉模拟量表评估)。
关键数值与推荐
- STOP-Bang评分≥3分定义为中高危OSA,评分包含打鼾、疲劳、目击呼吸暂停、血压、BMI、年龄、颈围、性别。
- 低氧血症定义为SpO2<90%持续>10秒。
- 严重低氧血症定义为SpO2≤75%或SpO2≤90%持续≥60秒。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Propofol sedation in patients with Obstructive Sleep Apnea (OSA) frequently induces hypoxemia, posing significant clinical risks. Esketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, may reduce propofol requirements while preserving respiratory stability, but its efficacy in OSA patients remains unproven. At the studied dose (0.25 mg/kg), esketamine's potential side effects (transient hypertension) are expected to be mild and self-limited. Therefore, we aimed to test whether low-dose esketamine (0.25 mg/kg) can reduce the incidence of hypoxemia in moderate-to-high risk OSA patients during propofol-based painless gastroscopy. METHODS: This single-center, double-blind, randomized controlled superiority trial will enroll 294 patients (STOP-Bang score ≥ 3, 18-90 years, STOP-Bang = Snoring, Tiredness, Observed apnea, Pressure [blood], Body Mass Index [BMI], Age, Neck size, Gender.) undergoing gastroscopy. Participants will be randomized 1:1 to receive either esketamine (0.25 mg/kg) plus propofol or saline placebo plus propofol, stratified by age (18-65 vs. > 65 years) and OSA severity (STOP-Bang 5-6 vs. ≥ 7). The primary outcome is the incidence of hypoxemia (Peripheral Oxygen Saturation [SpO2] < 90% for > 10 s). Secondary outcomes include severe hypoxemia (SpO2 ≤ 75% or ≤ 90% for ≥ 60 s), duration of hypoxemia, emergency airway management, propofol consumption, hemodynamic stability, involuntary body movements, procedure/recovery times, and clinician satisfaction (measured via 10-cm Visual Analog Scale [VAS]). DISCUSSION: This protocol rigorously evaluates esketamine's potential to improve sedation safety in OSA patients, addressing a critical gap in peri-procedural care. TRIAL REGISTRATION: Chinese Clinical Trial Registry (ChiCTR2500099420). Registered on March 24, 2025 (Supplementary File 2). Si-Qi Hao is a co-first author with the same contribution as the first author. The corresponding author is Li-Xin An.
引用
- Li XM, Hao SQ, Qi XR, et al. Effects of low-dose esketamine on hypoxemia during gastroscopy in patients with moderate-to-high risk obstructive sleep apnea: protocol for a prospective, randomized, controlled trial. Trials. 2025. PMID: 41013777. doi:10.1186/s13063-025-09098-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。